Tat-Beclin 1 is a cell-penetrating autophagy-inducing peptide composed of the HIV-1 Tat protein transduction domain fused to a fragment of Beclin-1 (a key autophagy protein). It was developed to pharmacologically enhance autophagy — the cellular self-cleaning process that degrades damaged organelles and misfolded proteins. In animal models, it has shown antiviral, anti-tumor, and lifespan-extending effects. It represents a targeted approach to activating autophagy without the broad metabolic effects of caloric restriction or rapamycin.
Category: Anti-Aging / Autophagy. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical. Published in top journals (Nature, Cell) but no human clinical trials.
The Beclin-1 fragment disrupts the interaction between Beclin-1 and its negative regulator GAPR-1 (also called Golgi-associated plant pathogenesis-related protein 1), freeing Beclin-1 to initiate autophagosome formation. The Tat domain provides cell-penetrating capability, delivering the active…
Safety considerations: No human safety data; Animal studies show tolerability at effective doses; Theoretical risk of excessive autophagy damaging healthy cells.
Reviewed by the PeptideAtlas Editorial Team.
| Half-life | ~1-2 hours (estimated, peptide rapidly degraded) |
|---|---|
| Bioavailability | Cell-penetrating — enters cells but systemic PK unknown in humans |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Research compound. No FDA filing. |
Related peptides: Rapamycin.
Both induce autophagy but through different mechanisms. Fasting activates autophagy broadly via AMPK/mTOR modulation. Tat-Beclin 1 specifically releases Beclin-1 from negative regulation, directly activating the autophagosome formation machinery. Tat-Beclin 1 may provide more targeted autophagy induction without the metabolic stress of fasting.
Tat-Beclin 1 is a cell-penetrating autophagy-inducing peptide composed of the HIV-1 Tat protein transduction domain fused to a fragment of Beclin-1 (a key autophagy protein). It was developed to pharmacologically enhance autophagy — the cellular self-cleaning process that degrades damaged organelles and misfolded proteins. In animal models, it has shown antiviral, anti-tumor, and…
On the PeptideAtlas A–F scale, Tat-Beclin 1 is rated D (Preclinical Only). Mostly animal or preclinical evidence
Preclinical. Published in top journals (Nature, Cell) but no human clinical trials.
The Beclin-1 fragment disrupts the interaction between Beclin-1 and its negative regulator GAPR-1 (also called Golgi-associated plant pathogenesis-related protein 1), freeing Beclin-1 to initiate autophagosome formation. The Tat domain provides cell-penetrating capability, delivering the active peptide across cell membranes. Once inside, the released Beclin-1 peptide promotes Class III PI3K…